Popular search terms:
Search Results
69 results found-
As is with other influenza vaccines, children who have received the appropriate course of FLUAD® Pediatric or another seasonal influenza vaccine are considered to be primed.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/20240417approvede139338ctrl285766fluadpm-asu-20242025.pdf -
Therefore, inactivated influenza vaccines are standardized to contain the hemagglutinin of influenza virus strains representing the influenza viruses likely to circulate in Canada in the upcoming winter on the basis of the recommendations from the World Health Organization (WHO) and the National Advisory Committee on Immunization (NACI).
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/flucelvax-quad_en-clean-pm_asu-2024-2025_watermark.pdf -
FLUCELVAX® QUAD Influenza Vaccine (surface antigen, inactivated, prepared in cell cultures) Page 8 of 30 Percentages of Subjects with Any (Severe) Solicited Reactions3 18 to less than 65 years of age ≥ 65 years of age Trivalent Influenza Trivalent FLUCELVAX® FLUCELVAX® QUAD Vaccine Influenza Vaccine QUAD N=663 TIV1c TIV2c TIV1c TIV2c N=656 N=330 N=327 N=340 N=336 Fever:
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/20240416_285764_flucelvax-quad_en-clean-pm_asu-2024-2025.pdf -
9.2 Drug Interactions Overview No interaction studies have been performed on interaction between influenza vaccines in general and other vaccines or medications.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/20240416_285754_afluria-tetra_en-clean-pm_asu-2024-2025.pdf -
FLUAD® Influenza vaccine (surface antigen, inactivated, adjuvanted with MF59® is now preferentially recommended by the Comité sur l’immunisation du Québec for adults 65 years of age and older.
https://www.cslseqirus.ca/news/fluad-adjuvanted-flu-vaccines-for-quebec-seniors-csl-seqirus-welcomes-the-ciq-recommendation -
Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
https://www.cslseqirus.ca/news/recently-published-real-world-evidence-study -
CSL Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.
https://www.cslseqirus.ca/our-company -
CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government’s outbreak and preparedness response.
https://www.cslseqirus.ca/news/csl-seqirus-announces-us-government-award-in-response-to-avian-influenza -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.ca/news/news-archives -
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
https://www.cslseqirus.ca/